Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Protagonist Therapeutics (NASDAQ:PTGX) has scheduled a conference call and webcast for Monday, June 30th at 4:30 pm ET to announce its oral obesity development candidate. The presentation will include details about in vitro and pre-clinical proof-of-concept study results.
Investors can access the call through US dial-in (1-877-407-0752) or international dial-in (1-201-389-0912) using Conference ID 13754335. A webcast replay will be available on the company's Investor Relations webpage after the event.
Protagonist Therapeutics (NASDAQ:PTGX) ha programmato una conference call e una webcast per lunedì 30 giugno alle 16:30 ET per annunciare il suo candidato per lo sviluppo orale contro l'obesità. La presentazione includerà dettagli sui risultati degli studi di prova di concetto in vitro e pre-clinici.
Gli investitori possono partecipare alla chiamata tramite numero US (1-877-407-0752) o numero internazionale (1-201-389-0912) utilizzando l'ID conferenza 13754335. Una registrazione della webcast sarà disponibile sulla pagina Investor Relations della società dopo l'evento.
Protagonist Therapeutics (NASDAQ:PTGX) ha programado una llamada de conferencia y una transmisión en vivo para el lunes 30 de junio a las 4:30 pm ET para anunciar su candidato para el desarrollo oral contra la obesidad. La presentación incluirá detalles sobre los resultados de estudios de prueba de concepto in vitro y preclínicos.
Los inversores pueden acceder a la llamada mediante marcación en EE.UU. (1-877-407-0752) o internacional (1-201-389-0912) usando el ID de conferencia 13754335. Una repetición en la web estará disponible en la página de Relaciones con Inversores de la compañía después del evento.
Protagonist Therapeutics (NASDAQ:PTGX)는 6월 30일 월요일 오후 4시 30분 ET에 구두 비만 치료 후보물질 발표를 위한 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 발표에는 시험관 내 및 전임상 개념 증명 연구 결과에 대한 세부 정보가 포함됩니다.
투자자들은 미국 내 전화(1-877-407-0752) 또는 국제 전화(1-201-389-0912)를 통해 컨퍼런스 ID 13754335를 사용하여 콜에 참여할 수 있습니다. 이벤트 후 회사 투자자 관계 웹페이지에서 웹캐스트 재생을 이용할 수 있습니다.
Protagonist Therapeutics (NASDAQ:PTGX) a programmé une conférence téléphonique et une webdiffusion pour le lundi 30 juin à 16h30 ET afin d’annoncer son candidat au développement oral contre l’obésité. La présentation comprendra des détails sur les résultats des études de preuve de concept in vitro et précliniques.
Les investisseurs peuvent accéder à l’appel via le numéro américain (1-877-407-0752) ou international (1-201-389-0912) en utilisant l’ID de conférence 13754335. Une rediffusion en webdiffusion sera disponible sur la page Relations Investisseurs de la société après l’événement.
Protagonist Therapeutics (NASDAQ:PTGX) hat eine Telefonkonferenz und Webcast für Montag, den 30. Juni um 16:30 Uhr ET angesetzt, um seinen oralen Entwicklungskandidaten gegen Adipositas vorzustellen. Die Präsentation wird Details zu den in vitro- und präklinischen Proof-of-Concept-Studienergebnissen enthalten.
Investoren können über die US-Einwahlnummer (1-877-407-0752) oder die internationale Einwahlnummer (1-201-389-0912) mit der Konferenz-ID 13754335 an dem Anruf teilnehmen. Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Investor-Relations-Webseite des Unternehmens verfügbar sein.
- None.
- None.
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below
NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
When is Protagonist Therapeutics (PTGX) hosting its conference call about the obesity drug candidate?
How can investors access Protagonist Therapeutics' obesity drug candidate announcement?
What will Protagonist Therapeutics (PTGX) discuss in their upcoming conference call?
Where can I find the replay of Protagonist Therapeutics' obesity drug announcement?
